access and potentially subject sarcoma patients to additional difficulties surrounding diagnosis and treatment.
Previous investigations have found that increased hospital volumes were associated with more favorable outcomes in various forms of cancer [3] [4] [5] and surgical procedures. [6] [7] [8] We used the National Cancer Database (NCDB) to further investigate the influence of facility volume on treatment decisions and oncologic outcomes in soft tissue sarcoma. The NCDB is a robust database that captures more than 70%
of all cancers reported in the United States, and is sponsored jointly by the American College of Surgeons and the American Cancer Society. It is viewed as an important tool for questions involving cancer treatment in the United States. 9 The NCDB has previously been utilized for investigations in sarcoma [10] [11] [12] and the effect of facility volume on some cancer outcomes, [13] [14] [15] but not the effect of facility volume in sarcoma.
Our goal was to use the NCDB to create a propensity score matched analysis comparing low-volume and high-volume facilities.
Our primary outcome of interest was overall survival at 2, 5, and 10 years, with secondary outcomes of treatment decisions (use of radiation or chemotherapy, type of surgery) and treatment outcomes (positive margins, 30-day readmissions).
| MATERIALS AND METHODS
We queried the NCDB from 1998 to 2012 to capture all patients 18 years of age and older with a diagnostically confirmed STS in the upper or lower extremity treated with surgical excision. We excluded any subjects with metastatic disease, unknown staging information, or unknown vital status. Any patients with an additional malignancy, other than the known STS, were excluded to reduce the possibility of recording death or adverse events from an unrelated condition.
Similarly, any patients with missing data for any of our variables of interest were removed from the analysis. We obtained patient age, sex, race, insurance status, distance to treating facility, tumor grade, tumor size, and tumor site directly from the database. We included undifferentiated pleomorphic sarcoma, fibrosarcoma, liposarcoma, leiomyosarcoma, synovial sarcoma, malignant peripheral nerve sheath tumor (MPNST), and their subtypes. We did not include welldifferentiated liposarcoma (atypical lipomatous tumors) or dermatofibrosarcoma protuberans due to their indolent course and low risk to metastasize. We used two socioeconomic measures, ZIP code based median household income and percentage of population with a high school degree, to create a composite socioeconomic (SES) summary variable, as has been done in previous reports. 16, 17 Our primary outcome of interest was overall survival after treatment for sarcoma, measured at 2-, 5-, and 10-years post treatment. Institutions that participate in the NCDB are required to submit survival data annually, which is reported as all-cause survival.
Further investigation into cause of death, and therefore cause-specific survival, is not possible. We also investigated secondary outcomes of treatment decisions (use of radiation or chemotherapy and type of surgery) and treatment results (surgical margins and 30-day readmissions). Radiation and chemotherapy are only recorded in the database when used in the first course of treatment. Margins classified as microscopic (eg, an R1 resection) and macroscopic (eg, an R2 resection) were both considered "positive."
| Statistical analysis
A propensity score analysis, consisting of matching, stratification, and logistic regression of clinically important predictor variables, is a powerful tool for reducing selection bias in observational studies by mimicking aspects of randomization. 18 Prior investigations have utilized a similar technique to study the volume-outcome relationship in health care. 13, 19 In this study, propensity scores were used to match (22) 545 (22) 522 (21) Leiomyosarcoma 870 (16) 319 (13) 311 (13) Synovial sarcoma 268 (5) 154 (7) 179 (7) MPNST+ 103 (2) 47 (2) 57 (2 The mean distance traveled to receive treatment at a high-volume center was substantially farther than low-volume hospitals (84 miles vs 39 miles, P < 0.001) ( Table 2 ). There was no clear difference in the frequency of 30-day readmissions (7% vs 7%, P = 0.804) or limb salvage surgeries (92% vs 92%, P = 0.667) in low-or high-volume centers. High-volume centers revealed greater use of chemotherapy (22% vs 17%, P < 0.001), a similar use of external beam radiation (55% vs 52%, P= 0.108), and fewer positive surgical margins (12% vs 17%,
High-volume centers demonstrated a favorable overall survival at 2, 5, and 10 years after treatment compared to low-volume hospitals (Table 3 ). The differences were apparent by 2 years and maintained 10 years after diagnosis ( Figure 1) .
A multivariate Cox proportional hazards model identified several independent prognostic factors for mortality in extremity STS (Table 4) .
In decreasing magnitude, risk factors for increased mortality at 5 years Gutierrez et al 29 we did not find that the amputation rates differed between high-and low-volume centers. This could possibly be explained by a more modern investigative cohort, as our period of interest was 1-2 decades later than the previous study and at a time when limb salvage surgery is ubiquitous and the standard-of-care for extremity STS.
We found a lower rate of positive margins and improved survival at high-volume facilities. These are important findings as, in most cases, sarcoma excision is performed with the goal of negative margins, and a positive margin may reflect a failure of planning or execution.
Similarly, prolonged survival is the primary goal of cancer treatment, and is the most meaningful metric when comparing the outcomes of two groups. Contrary to prior reports, we found a clear difference in survival that was apparent by 2 years post treatment and maintained to 10 years. We may have been able to detect this difference given our use of propensity score matching, as lower-grade and smaller tumors are overrepresented at low-volume centers and have an inherently favorable prognosis. 29 The relationship of survival to facility volume was apparent using a risk-adjusted cohort in a multivariate model for which other patient, tumor, and treatment factors were accounted.
Thus, our data clearly demonstrate that facility volume is an independent risk factor for diminished survival in extremity STS.
This result is not surprising given similar volume-based conclusions in pancreatic and esophageal cancers, both rare conditions requiring a team of experts for optimal management. 20 However, the ultimate implications of these findings, specifically regarding the delivery of specialty care, are interesting and complex.
A prior report by Halm et al 32 There are several limitations to this investigation. First, our analysis was centered on hospital volume, not surgeon volume.
Prior reports have shown mixed correlations between hospital and surgeon volume and outcomes 8, 13, 36, 37 ; we believe that facility volume is a more important metric in sarcoma as it is a condition that requires multidisciplinary care and optimal treatment is dependent on more than individual surgical prowess. Next, the NCDB reports overall survival only and some of our patients may have died from causes unrelated to their underlying sarcoma.
However, this would have been an equal risk in both cohorts and we have no reason to believe that death from other causes would be dramatically different between the groups. The cut-off of 10 STS annually that we chose to distinguish between high-and lowvolume centers is supported by prior reports, 30 but is relatively arbitrary and underestimates the total number of sarcomas treated by excluding bone, metastatic, recurrent, retroperitoneal, uterine, and head and neck sarcoma. We believe this approach is justified, as our goal was not to determine an optimal number of sarcomas for a center to treat, but rather to investigate general differences in treatment and outcome as a function of relative facility volume.
Future work should determine if there are a minimum number of cases of STS that a facility should treat to attain optimal outcomes.
Finally, a common limitation of most large data sources is the lack of information given the specifics of individual patient presentations and treatment decision-making. In particular, "chemotherapy"
is recorded generally, and the specific drugs and dosages are unknown. It is possible that a specific systemic intervention did demonstrate a survival benefit that we were not able to detect given the limitations of the database. Providers and patients alike continue to be in dire need of novel and effective systemic treatments in sarcoma.
Our results support the conclusion that high-volume centers provide superior outcomes, in the form of fewer positive margins and improved survival, in patients with soft tissue sarcoma. Treating providers and patients alike should be aware that, although highvolume centers may be at greater distance and present increased logistical challenges, management by a team of experienced specialists could provide real benefits in long-term overall survival. Future efforts should focus on strategies to improve access to regional facilities with infrastructure and experience in sarcoma treatment.
